Millions of Americans are fighting insurance companies for access to GLP-1 drugs that already exist. Meanwhile, one 79-year-old man quietly received something better — an unapproved weight-loss drug that most people don’t even know about yet. STAT News reported on June 23, 2026, that Eli Lilly and the FDA granted single-patient expanded access to retatrutide, the company’s investigational triple-agonist obesity injectable. The patient’s identity remains unknown. The silence around it is telling.
What Retatrutide Is – And Why One Person Getting It Matters
The drug isn’t on pharmacy shelves — and that’s exactly what makes this case so striking.
Early trial data showed 24–28% body weight reduction over roughly 72–80 weeks, approaching bariatric surgery results, from a needle. Retatrutide targets three metabolic receptors simultaneously (GLP-1, GIP, and glucagon), and it is not FDA-approved. Normally, a clinical trial slot is the only way to access it. Expanded access — the FDA’s compassionate use pathway — exists for seriously ill patients who’ve exhausted approved options and cannot enroll in trials.
Here’s what’s publicly known about this case:
- The request was filed in April 2026 by Dr. Ranganath Muniyappa, an NIH endocrinologist, on behalf of a 79-year-old male patient
- The patient reportedly had refractory obesity, obstructive sleep apnea, and pulmonary hypertension, with only moderate weight loss after roughly a year on tirzepatide
- The ClinicalTrials.gov listing (NCT07629401) is strikingly bare — no condition listed, no eligibility criteria, no location
- Sources told STAT the case drew attention from “top health officials,” suggesting a well-connected patient
Richard Klein, former architect of the FDA’s expanded-access program, told STAT the listing is “very wrong” — that “no one would know what it is from the listing, or what it’s for.” More than a dozen experts called the arrangement highly unusual. Expanded access for a common condition like obesity, rather than a rare terminal illness, is nearly unheard of. Lilly spokesperson Misty Fuller said only that the company follows “all applicable regulations” — without explaining why this patient qualified ahead of millions seeking similar relief.
The Question Nobody at the White House Will Answer
When both the White House and HHS decline to say yes or no, the silence becomes its own kind of answer.
The patient was 79 when the April request was filed. Donald Trump turned 80 in mid-June. The treating physician works at the NIH. STAT asked the White House and HHS directly whether Trump is the patient. Neither confirmed. Neither denied. HHS spokesperson Emily Hilliard offered a generic statement praising expanded access programs.
That non-denial landed against a pointed backdrop: Trump’s administration has simultaneously championed GLP-1 pricing deals with Eli Lilly through the TrumpRx initiative. If the same individual negotiating drug access policy for millions of Americans is also privately receiving an unapproved next-generation version of that drug, the conflict-of-interest questions write themselves. To be clear, no public medical records confirm Trump has obstructive sleep apnea or pulmonary hypertension, and no official source has confirmed his identity as the patient.
Millions of Americans are still being denied insurance coverage for drugs that already exist and are already approved. Someone received the version that hasn’t been approved yet. That gap between who the system serves and who it was designed to serve is worth examining closely.
